Cardiogen

Cardiogen is a synthetic tetrapeptide composed of alanine, glutamic acid, aspartic acid, and arginine (Ala-Glu-Asp-Arg, single-letter code AEDR). Molecular weight is approximately 489.5 Da. It belongs to the Khavinson Cytogen class developed at the St. Petersburg Institute of Bioregulation and Gerontology and is marketed as the synthetic counterpart to the cardiac Cytomax Chelohart.

The Khavinson bioregulator program produced two parallel compound classes. Cytomaxes are organ-specific peptide extracts from young animal tissues, containing heterogeneous mixtures of short peptides up to several kDa. Cytogens are short synthetic peptides, typically two to four amino acids, designed to reproduce single defined sequences identified within the corresponding Cytomax. For cardiac tissue, the Cytomax is Chelohart and the Cytogen is Cardiogen. The sequence AEDR is reported in the Russian patent and commercial literature; the related research peptide Pinealon shares the EDR core motif.

The compound is described across the Khavinson group's body of work, including the 2021 systematic review by Khavinson and colleagues on peptide regulation of gene expression. The 2009 paper by Chalisova and colleagues in Advances in Gerontology examined Cardiogen effects on myocardial tissue culture from young and aged rats, reporting stimulation of cardiomyocyte proliferation at picomolar concentrations.

The Human Evidence

The compound-specific human evidence base for Cardiogen consists of:

• Russian-institution clinical observation studies in elderly patients with coronary heart disease, hypertension, and chronic heart failure
• Use as part of broader Khavinson geroprotective protocols in Russian medical centers
• Manufacturer documentation describing improvement in standard cardiovascular parameters after 30-day courses

Independent confirmation by Western groups is sparse. PubMed search for "Cardiogen AEDR" or "Ala-Glu-Asp-Arg cardiac" returns Khavinson-affiliated publications and chemical-characterization papers. No registered ClinicalTrials.gov trial exists for Cardiogen as of May 2026. The clinical-outcome claims (reduced angina episodes, improved exercise tolerance, lower medication burden) come from non-randomized open-label observations.

A reader evaluating Cardiogen should weigh two facts together. First, the Khavinson group has produced a coherent decades-long theoretical framework for short-peptide gene-expression bioregulation, with peer-reviewed mechanistic publications across multiple Cytogens. Second, the compound-specific clinical data for Cardiogen has not been independently replicated. Both should be acknowledged honestly.

Regulatory and Legal Status

FDA. No approval. Not listed on the bulk drug substances list. Importation is permitted only as a research chemical labeled "not for human consumption."

EMA. No approval.

Russia. Registered as a biologically active dietary supplement. Sold in oral capsule format through the Khavinson distribution network.

WADA. Not on the 2026 Prohibited List.

The proposed mechanism follows the broader Khavinson short-peptide bioregulation model with cardiac-tissue specificity.

Cellular entry. The AEDR tetrapeptide is hypothesized to enter cells through peptide transporters (PEPT1, PEPT2), reach the cytoplasm, and translocate to the nucleus. The small molecular weight facilitates passive diffusion through nuclear pores.

DNA and histone binding. The Khavinson group's 2013 paper by Fedoreyeva and colleagues demonstrated that short peptides including AEDR interact with FITC-labeled histones and deoxyribooligonucleotides in vitro. The proposed model treats AEDR as binding selectively to specific promoter regions of cardiac genes, modulating their expression.

Downstream effects. Khavinson group publications describe Cardiogen producing the following effects in animal myocardial tissue culture:

• Stimulation of cardiomyocyte proliferation at picomolar concentrations
• Modulation of p53-mediated apoptosis pathways
• Restoration of age-related decline in cardiomyocyte protein synthesis
• Influence on cardiac fibroblast activity

The specific genes affected have not been mapped in independent transcriptomic studies. Cardiac-tissue-specificity claims rest on functional observations in tissue culture rather than direct demonstration of cardiac-promoter binding selectivity in vivo.

Human pharmacokinetic data is not published. Plasma half-life, tissue distribution, oral bioavailability, and excretion kinetics for Cardiogen in humans have not been characterized in any peer-reviewed pharmacokinetic study. Like other tripeptides and tetrapeptides, oral Cardiogen faces gut hydrolysis to free amino acids; the Khavinson group has addressed this by proposing partial PEPT1 absorption and signaling through gut-mucosa interfaces.

Reported effects come from Russian-institution clinical observation studies and from user reports in research-chemical communities outside Russia.

Russian-institution reports describe improvements in symptom scores for chronic ischemic heart disease, modest reductions in blood pressure variability, improvement in exercise tolerance, and use as an adjunct in post-myocardial-infarction rehabilitation protocols.

Research-chemical user reports include subjective improvements in exercise endurance, perceived improvement in cold-extremity symptoms, and reports of reduced palpitations. These reports are anecdotal, unverified for vial identity, and not controlled for placebo or co-intervention.

None of these effects has been quantified in a placebo-controlled trial published in an English-language indexed journal. The Russian institutional reports are non-blinded.

No standardized human dosing protocol supported by independent pharmacokinetic data exists for Cardiogen.

The Russian retail product is dosed as 1 to 2 capsules once or twice daily before meals for a 30-day course, repeated 2 to 3 times per year. Each capsule contains approximately 20 mg of active peptide. After the Cytogen course, the Khavinson protocol recommends transitioning to Chelohart capsules as the Cytomax.

Research-chemical Cardiogen is sold as 20 mg lyophilized vials. Subcutaneous dosing protocols in research-chemical communities use 200 to 500 mcg daily over 10 to 20 day cycles. These protocols are extrapolated from generic Khavinson-bioregulator recommendations and are not supported by Cardiogen-specific human pharmacokinetic studies.

The course-and-cycle pattern reflects the Khavinson claim that bioregulator effects persist between courses through induced gene-expression changes. Independent confirmation of optimal cycle spacing for Cardiogen is absent.

The Khavinson bioregulator class has a notably benign published adverse-event profile. The Russian manufacturer documentation for Cardiogen lists individual intolerance, pregnancy, and lactation as the only contraindications. No serious adverse events have been formally reported in Russian-language clinical publications.

This is consistent with the tetrapeptide structure. The constituent amino acids (alanine, glutamic acid, aspartic acid, arginine) are common dietary amino acids. Tetrapeptide doses at the microgram-to-milligram level fall within or below normal dietary peptide exposure. Acute toxicity is mechanistically unlikely.

The relevant safety question is not acute toxicity but chronic effects on cardiac gene expression. Long-term human safety data with controlled endpoints does not exist. The Khavinson group reports cumulative safety experience from decades of Russian clinical use, which is informative but is not equivalent to a structured long-term safety database.

A theoretical concern raised in Western reviews is that any compound claimed to stimulate cardiomyocyte proliferation could in principle interact with arrhythmia substrates or with established cardiac pathology in unpredictable ways. This concern has not been formally evaluated. Drug-drug interaction data with antihypertensives, anticoagulants, or antiarrhythmic agents is absent.

Within the Khavinson system, Cardiogen is the initial-phase Cytogen for cardiac bioregulation. The standard protocol transitions to Chelohart (Cytomax) for extended support. For comprehensive cardiovascular coverage, Cardiogen is combined with Ventfort (vascular Cytomax) and Vesugen (vascular Cytogen).

For broader geroprotective stacks, Cardiogen appears alongside Epitalon (pineal), Prostamax (prostate), and Pinealon (neural). No combined-stack human trial has been published.

External comparators by claimed effect are ACE inhibitors, ARBs, beta-blockers, statins, and antiplatelet agents. These have decades of Phase 3 randomized trial data demonstrating reduction in cardiovascular events. Cardiogen has no such evidence base and should not be treated as a substitute for prescribed cardiac therapy in any clinical context.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.